Navigation Links
PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
Date:8/30/2010

PRINCETON, N.J., Aug. 30 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced today that Anthony Maida, PhD has joined the Company as Vice President, Clinical Research. Dr. Maida will be responsible for leading PharmaNet's oncology team.

"Anthony's experience spans the drug development process. He has a unique strength in his well balanced expertise across strategic, operational and financial aspects of the business," said Dr. Robert Reekie, Chief Operating Officer and Senior Executive Vice President, Late Stage Development. "We are pleased to have Anthony as part of our outstanding oncology team."

Dr. Maida has more than twenty years of experience providing strategic, operational, and financial expertise to pharmaceutical companies that are focused primarily in the area of oncology.  Most recently, he ran his own consulting firm providing both pharmaceutical product development and capital raising capabilities to pharmaceutical firms, working with venture capital funds and investment banks. Prior to joining the pharmaceutical industry, Dr. Maida worked for Lockheed Corporation in a number of key financial roles.

Dr. Maida earned Bachelor of Arts degrees from the University of Santa Clara and San Jose State University, a Masters of Business Administration degree from the University of Santa Clara, a Masters degree in Toxicology from San Jose State University and a PhD in Tumor Immunology, from the University of California, Davis.  

About PharmaNet Development Group, Inc. PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2300 employees in 33 countries and more than 38 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  Contact: Anne-Marie HessPhone: (609) 951-6842E-mail: ahess@pharmanet.com
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
2. SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
3. Christopher Brennan Joins PharmaNet Development Group as General Counsel
4. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
5. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
6. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
7. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
8. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
11. Torbjorn Bjerke Appointed as new CEO for Karolinska Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Malden, MA (PRWEB) , ... January 18, 2017 ... ... announced today that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation ... Medical Center in Valley Stream, NY. The procedure was an anterior cervical discectomy ...
(Date:1/18/2017)... OF PRUSSIA, PA (PRWEB) , ... January 18, ... ... disrupt clinical operations again at the CHI SCOPE Summit for Clinical Ops Executives ... AstraZeneca in engaging panel discussions to examine vital clinical research issues such as ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017  HUYA Bioscience ... of China,s pharmaceutical innovations, announced ... of Sciences Innovation and Investment Company (referred to as ... commercializing biomedical innovations discovered by leading scientists at CAS ... world. HUYA is the first company to ...
(Date:1/17/2017)... West Point, IA (PRWEB) , ... January 17, ... ... approval from China for Balance™ GT soybeans. The new Balance™ GT Soybean Performance ... tolerance to glyphosate and isoxaflutole, the active ingredient in the new Balance® Bean ...
Breaking Biology Technology:
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
(Date:12/20/2016)... 2016 The rising popularity of mobility ... is stoking significant interest in keyless access systems. ... low energy (BLE), biometrics and near-field communication (NFC) ... of wireless technologies in the automotive industry. This ... access systems opens the market to specialist companies ...
(Date:12/19/2016)... , España y TORONTO , 19 de ... con Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, ... clínicos en varios tipos de tumor en 2017, con múltiples sitios ... ... su clase con objetivo en el factor inhibidor de leucemia (LIF), ...
Breaking Biology News(10 mins):